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ABSTRACT
Macrophagesmediate innate immune responses that recognise foreign
pathogens, and bacterial lipopolysaccharide (LPS) recruits a signalling
pathway through Toll-like receptor 4 (TLR4) to induce pro-inflammatory
cytokines and reactive oxygen species (ROS). LPS activation also
skews themetabolismofmacrophages towards a glycolytic phenotype.
Here, we demonstrate that the LPS-triggered glycolytic switch is
significantly attenuated in macrophages deficient for glutathione
transferase omega-1 (GSTO1, note that GSTO1-1 refers to the
dimeric molecule with identical type 1 subunits). In response to LPS,
GSTO1-1-deficient macrophages do not produce excess lactate, or
dephosphorylate AMPK, a key metabolic stress regulator. In addition,
GSTO1-1-deficient cells do not induce HIF1α, which plays a key role in
maintaining the pro-inflammatory state of activated macrophages. The
accumulation of the TCA cycle intermediates succinate and fumarate
that occurs inLPS-treatedmacrophageswasalsoblocked inGSTO1-1-
deficient cells. These data indicate that GSTO1-1 is required for
LPS-mediated signalling in macrophages and that it acts early in the
LPS–TLR4 pro-inflammatory pathway.
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INTRODUCTION
Innate immunity is considered as the first line of defence against
invading pathogens in mammals. The activation of macrophages
resulting from the interaction of the bacterial cell wall component
lipopolysaccharide (LPS) with Toll-like receptor 4 (TLR4) constitutes
a major pathway for the initiation of innate immune responses and the
development of inflammation. Inmacrophages, activation of TLR4by
LPS has been shown to recruit downstream signalling proteins and
induce the generation of reactive oxygen species (ROS) and pro-
inflammatory cytokines such as interleukin (IL)-1β, IL-6 and TNFα
(Doyle and O’Neill, 2006; Gill et al., 2010; Stoll et al., 2006; Zhang
and Ghosh, 2001; Zhou et al., 2010). In addition to their bactericidal
activity, their signalling role and their impact on the expression of
pro-inflammatory cytokines, theROSgenerated by theTLR4pathway
have also been shown to cause tissue damage and are central to
the progression and pathology of many inflammatory diseases
(Gill et al., 2010).
We have previously shown that Omega class glutathione
transferase-1 (GSTO1, note that GSTO1-1 refers to the dimeric
molecule with identical type 1 subunits) is essential for the generation
of cytosolic ROS after the activation of the TLR4 pro-inflammatory
cascade (Menon et al., 2014). GSTO1-1-deficient macrophages are
non-responsive to LPS and do not activate nuclear factor (NF)-κB and
NADPH oxidase 1 after TLR4 activation. Since their first description,
the Omega class GSTs have been investigated in relation to a number
of biologically significant pathways and clinical disorders including
drug resistance, Alzheimer’s disease, Parkinson’s disease, vascular
dementia and stroke, amyotrophic lateral sclerosis, the action of anti-
inflammatory drugs, the disposition of arsenic, susceptibility to
chronic obstructive pulmonary disease (COPD) and cancer (Allen
et al., 2012; Escobar-Garcia et al., 2012; Harju et al., 2007; Kölsch
et al., 2004; Li et al., 2003; Piacentini et al., 2012). Because
inflammation has been implicated in the pathology associated with
manyof these disorders it is important to understand themechanismby
which GSTO1-1 mediates inflammatory responses in macrophages.
Here, we have investigated the role of GSTO1-1 in the activation of
parallel pathways that generate mitochondrial ROS and indirectly feed
into TLR4 signalling. In light of recent studies showing that TLR4
activation by LPS skews macrophage metabolism towards a more
glycolytic phenotype (Freemerman et al., 2014;Haschemi et al., 2012;
Tannahill et al., 2013), we examined themetabolic profile of GSTO1-
1-deficient macrophages. We found that GSTO1-1 plays a key role in
determining the glycolytic phenotype of LPS-activated macrophages
and also dictates the redox processes in macrophages necessary to
mediate inflammatory responses.
RESULTS
GSTO1-1 mediates pro-inflammatory responses in
macrophages
LPS has previously been shown to increase mitochondrial ROS
generation and contribute to the pro-inflammatory response in
macrophages (Mo et al., 2014; Poltorak et al., 1998; Thimmulappa
et al., 2006). We confirmed this finding and measured a significant
(P=0.05) increase in mitochondrial ROS in LPS-treated J774.1A
non-silencing control cells. This response was absent in GSTO1-
knockdown cells (Fig. 1A), suggesting that GSTO1-1 is required for
mitochondrial ROS production in addition to its previously
demonstrated effect on cytosolic ROS (Menon et al., 2014). As a
consequence of the oxidative stress resulting from the increased
cytosolic and mitochondrial ROS, we found that there was a
significant decrease in the GSH:GSSG ratio of LPS-treated control
J774.1A cells (Fig. 1B). In comparison there was no change in
the GSH:GSSG ratio in GSTO1-knockdown cells treated with
LPS. This is consistent with the lack of ROS production in these
cells.
In subsequent studies, we evaluated changes in the transcript
levels of inflammatory markers that are influenced by oxidative
stress in macrophages. An increase in ROS levels and/or a decrease
in antioxidants such as glutathione have both previously been
demonstrated to induce the expression of cyclooxygenase-2 (COX-2,
also known as PTGS2) and inducible nitric oxide synthase (iNOS,Received 17 December 2014; Accepted 10 March 2015
1Department of Molecular Biosciences, John Curtin School of Medical Research,
Australian National University, Canberra, ACT 2600, Australia. 2Institute for
Molecular Bioscience, The University of Queensland, St Lucia 4072, Australia.
3School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute,
Trinity College Dublin, Dublin 2, Ireland.
*Author for correspondence (Philip.Board@anu.edu.au)
1982













also known as NOS2) in LPS-treated macrophages (D’Acquisto
et al., 1997; Raso et al., 2001; Wadleigh et al., 2000). The induction
of COX-2 and iNOS after LPS treatment was significantly
diminished in GSTO1-1-deficient macrophages (Fig. 1C,D). This
lack of response is possibly due to the lack of stimuli in the form of
increased ROS or decreased GSH (Chen et al., 1999). Similarly,
when LPS-activated non-silencing control J774.1A macrophages
were pre-treated with ML175, to inhibit GSTO1-1, the induction of
COX2 and iNOS was significantly attenuated (Fig. 1E,F). This
result strongly suggests that the action of GSTO1-1 on LPS-initiated
inflammation is dependent on its catalytic activity.
Mitochondrial dysfunction in LPS stimulatedmacrophages is
abrogated in GSTO1 knockdown cells
In addition to its effect on mitochondrial ROS production, we also
examined the effect of GSTO1-1 on the previously noted decrease
in mitochondrial membrane potential (ψ) that occurs after LPS
stimulation (Mo et al., 2014). We detected a significant (P<0.05)
decrease in the mitochondrial membrane potential in LPS treated
J774.1A non-silencing control cells. In contrast, LPS did not
significantly change the mitochondrial membrane potential of
GSTO1-1-deficient cells (Fig. 2A).
It has been previously established that an altered mitochondrial
membrane potential is associated with an imbalance in the AMP:
ATP ratio that is monitored by AMP-activated protein kinase
(AMPK), a major sensor of intracellular energy status (Mo et al.,
2014). As recent evidence suggests that there is a substantial link
between energy homeostasis and redox state in macrophages
(Gauss et al., 2007; Maitra et al., 2009; Matsuzawa et al., 2005;
Meissner et al., 2008; Menon et al., 2014; Mo et al., 2014; West
et al., 2011), we further investigated the role of GSTO1-1 in
modulating the LPS-stimulated decrease in the mitochondrial
membrane potential by evaluating the amount of phosphorylated
AMPK (p-AMPK), which is indicative of the amount of activated
AMPK. The results indicate that the activation of AMPK to
p-AMPK is diminished by a pro-inflammatory stimulus such as
LPS, and this effect is dependent on GSTO1-1, given that normal
levels of p-AMPK remained in GSTO1-knockdown cells after
Fig. 1. GSTO1-1 mediates pro-
inflammatory responses in LPS-
activated macrophages. (A) LPS-treated
non-silencing control cells showed a
significant (*P=0.05) increase in
mitochondrial ROS which was absent in
the GSTO1-knockdown (GSTO1 KD)
cells. (B) As a consequence of increased
oxidative stress resulting from the
increased cytosolic and mitochondrial
ROS, a significant (*P<0.05) drop in the
GSH:GSSG ratio was measured in the
non-silencing control cells. The J774.1A
GSTO1-knockdown cells showed no
alteration in the GSH:GSSG ratio,
suggesting an overall absence of oxidative
stress in these cells. (C–F) Fold changes
in mRNA. (C,D) LPS-treated
macrophages deficient in GSTO1-1
showed a significantly (***P<0.001)
reduced induction of redox-sensitive pro-
inflammatory markers, such as COX2
(C) and iNOS (D). (E,F) The induction of
COX2 and iNOS was abolished in LPS-
activated macrophages pre-treated with
ML175, mimicking GSTO1-knockdown
cells and suggesting the catalytic
involvement of GSTO1-1 in LPS
signalling. All data are shown as the
mean±s.e.m. (n=3).
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LPS stimulation (Fig. 2B). To further determine whether the
LPS-triggered loss of p-AMPK is dependent on the catalytic activity
of GSTO1-1, we tested the ability of ML175 to maintain normal
p-AMPK levels. As shown in Fig. 2C, AMPK phosphorylation
was restored by ML175 treatment in a concentration-dependent
manner.
Reconfiguration of cellular metabolism during pro-
inflammatory polarization of M1 macrophages
The observed requirement for GSTO1-1 in the maintenance of the
normal mitochondrial response to LPS in macrophages and in the
activation of AMPK suggested that GSTO1-1 is also be required for
the well-documented shift in macrophage metabolism towards
glycolysis after LPS activation (Freemerman et al., 2014; Haschemi
et al., 2012; Tannahill et al., 2013).
We therefore compared the extracellular acidification rate
(ECAR) and oxygen consumption rate (OCR) of LPS-activated
GSTO1 knockdown and control macrophages. As shown in Fig. 3A,B,
a steady increase in the ECAR (reflecting increased glycolysis) in
control cells treated with LPS was blocked in GSTO1-knockdown
cells. In contrast, OCR levels (reflecting oxidative phosphorylation)
inversely mirrored ECARchanges in control cells. The OCR showed a
steady decline in control cells and there was no change in GSTO1-
deficient macrophages (Fig. 3B). To complement the ECAR
measurements in GSTO1-deficient cells, we quantified the lactate
secreted into the medium by the cells after LPS stimulation. As
expected, we measured a significant increase (P<0.001) in the
extracellular lactate levels in cells expressing non-silencing control,
confirming the shift in their metabolism away from mitochondrial
oxidative phosphorylation to glycolysis. However, the GSTO1-
knockdown cells did not alter their lactate secretion, confirming that
the cells did not respond to LPS and acquire a glycolytic phenotype
(Fig. 3C). Consistent with the requirement for GSTO1-1 in the
LPS-induced glycolytic shift, we also found that the inhibitor ML175
caused a concentration-dependent decrease in lactate production by
J774.1A cells after LPS treatment (Fig. 3D).
In addition to increased glycolysis through the Emden–Meyerhof
pathway, increased flux through the pentose phosphate pathway
(PPP) can also contribute to lactate production. Increased flux
through the PPP generates NADPH that is required by NADPH
oxidases to generate high levels of ROS after TLR4 activation. We
found that NADPH levels were significantly increased in
LPS-stimulated non-silenced J774.1A macrophage-like cells, but
no increase was observed in GSTO1-knockdown cells (Fig. 3E) or
in cells treated with ML175 (Fig. 3F).
LPS-inducedaccumulation of succinate and the stabilization
of HIF1α
The TCA cycle intermediate succinate is an inflammatory signal that
increases in macrophages following stimulation with LPS and the
subsequent metabolic shift (Tannahill et al., 2013). In metabolomics
experiments performed after LPS activation of non-silenced J774.1A
cells, we found the expected build-up of the Kreb’s cycle intermediate
succinate and a relatively lower accumulation of fumarate. This
response was abolished in GSTO1-deficient cells, reflecting the
absence of a glycolytic phenotype in these cells (Fig. 4A,B). In these
studies, the abundance of TCAmetaboliteswas normalized to the total
number of cells and to the amount of essential amino acids (Leu, Ile or
Met) detected in the cell lysates. Citrate levels also showed a similar
trend in LPS-treated control macrophages but remained unaltered in
GSTO1-1-deficient macrophages (Fig. 4C). Metabolomic profiling
also identified that the levels of the glycolytic intermediates glucose
6-phosphate and fructose 6-phosphate were dependent on the
expression of GSTO1-1 (Fig. 4D). This trend in sugar phosphates
was previously reported in macrophages overexpressing carbohydrate
kinase-like protein (CARKL, also known as SHPK) and was found to
dampen the pro-inflammatory responses of TLR4-activated
macrophages (Haschemi et al., 2012).
Previous studies have shown that the accumulation of succinate
during the LPS-mediated activation of macrophages stabilizes the
transcription factor HIF1α and promotes the transcription of IL-1β
(Tannahill et al., 2013). We found that the accumulation of HIF1α
normally triggered by LPS is blocked in GSTO1-1-deficient cells
(Fig. 4E).This is consistentwith the failure ofGSTO1-1-deficient cells
to accumulate succinate. In additional studies of HIF1α (Fig. 4F), we
found that inhibition of GSTO1-1 with ML175 mimicked the effects
of silencing GSTO1-1 in macrophages in a dose-dependent manner.
Modulating the metabolic profile of macrophages blocks the
activation of the M1-macrophage-like phenotype
To evaluate the consequences of disrupted metabolism in GSTO1-1
deficient cells, we measured the phagocytic ability of the cells both
qualitatively and quantitatively using two independent approaches in
order to determine whether the cells behave like M1 macrophages
uponLPS stimulation. J774.1Anon-silencing control cells internalized
fluorescently labelled dead bacteria efficiently indicating a collective
response of all TLRs to the presence of pathogenic agents in
the microenvironment. Further, J774.1A non silencing control cells
primed with LPS for 2 h prior to incubation with the fluorescently
labelled dead bacteria significantly enhanced phagocytosis (Fig. 5A).
Interestingly, GSTO1-deficient cells showed poor efficacy in the
Fig. 2. GSTO1-1 modulates mitochondrial
function and energy status in LPS-treated
macrophages. (A) The significant (*P<0.05)
decrease in the mitochondrial membrane potential
(ψ) in LPS-treated J774.1A non-silencing control
cells was absent in the GSTO1-1-deficient cells.
(B) The inhibitory effect of LPS on AMPK
phosphorylation in J774.1A macrophages is
reversed in GSTO1-1-deficient cells. (C) AMPK
activation was restored by ML175 in LPS-activated
macrophages. All data are shown as themean±s.e.m.
(n=3).
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internalization of the pathogenic particles and also remained
unstimulated after priming with LPS (Fig. 5A). Cell viability was
evaluated to eliminate any difference in the cell viability post bacterial
exposure (Fig. 5B). To further narrow down the non-responsiveness
of GSTO1-knockdown cells, latex beads coated with LPS were
applied to the cells to specifically activate TLR4. We found that
GSTO1-1-deficient cells failed to internalize the LPS-coated latex
micro particles (in red) to the extent seen with the non-silenced control
cells (Fig. 5C–E).
DISCUSSION
Previous studies have established that macrophages activated through
the LPS–TLR4 pathway produce ROS and develop a glycolytic
phenotype that is characterized by the increased production of lactate
and the accumulation of succinate, which stabilizes HIF1α and
regulates the expression of IL-1β. Recently, we demonstrated that
GSTO1-1 is required for the activation ofNF-κBand the production of
cytosolic ROS in macrophages stimulated by LPS (Menon et al.,
2014). In the present study, we have investigated the role of GSTO1-1
in the production of ROS during mitochondrial metabolism and the
development of a glycolytic phenotype inLPS-activatedmacrophages.
Our results show that GSTO1-1 is also required for the generation of
mitochondrial ROS, which, taken together with our previous data,
indicates that GSTO1-1 is a significant regulator of ROS production
and a determinant of redox balance in LPS-activated macrophages.
ROS are major mediators of cytotoxicity and are directly responsible
for much of the pathology that is associated with inflammation. As
inflammation contributes to the pathology and progression of a wide
range of disorders this finding might explain the previously reported
associations between genetic variations in GSTO1 and Alzheimer’s
disease, Parkinson’s disease, vascular dementia and stroke,
amyotrophic lateral sclerosis and chronic obstructive pulmonary
disease (COPD) (Allen et al., 2012; Escobar-Garcia et al., 2012;
Harju et al., 2007; Kölsch et al., 2004; Li YJ et al., 2003; Piacentini
et al., 2012). The investigation of GSTO1-1 in other disorders that are
influenced by inflammation would appear to be warranted.
Our present data also indicates that GSTO1-1 is required for the
major metabolic shift to a glycolytic phenotype that occurs in
Fig. 3. GSTO1-1 deficiency blocks the
development of a glycolytic phenotype
in LPS-activated macrophages. (A) The
LPS-induced increase in ECARmeasured
in non-silencing J774.1A macrophages
was largely absent in the GSTO1-1-
deficient macrophages. (B) The LPS-
induced decrease in the OCR observed in
non-silencing J774.1A macrophages did
not occur in GSTO1-1 deficient
macrophages. (C) Significantly (**P<0.01)
increased extracellular lactate levels
confirmed the high rate of LPS-induced
extracellular acidification in control cells,
whereas the level of extracellular lactate
was unchanged in the supernatant from
GSTO1-1-deficient cells treated with LPS.
(D) Wild-type J774.1A macrophages
treated with LPS showed a significant
(*P<0.05) dose-dependent decrease in
the extracellular lactate level when
GSTO1-1 was inhibited with ML175.
(E,F) NADPH levels were significantly
(**P<0.01) increased in LPS-stimulated
J744.1A non-silencing macrophage cells
(E) but no increase was measured in the
GSTO1-1-deficient cells and in cells
treated with ML175 (F). All data are shown
as the mean±s.e.m. (A,B, n=5; C–F, n=3).
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LPS-activated macrophages. We found that GSTO1-1 deficiency
blocks the increased production of lactate and the decrease in
oxygen consumption that normally follows LPS stimulation. In
addition, metabolomic studies showed that GSTO1-1 deficiency
blocked the accumulation of succinate that has been shown to be a
major inflammatory signal that stabilizes HIF1α allowing the
subsequent induction of IL-1β. This finding was supported by the
observation that HIF1α does not accumulate in GSTO1-1-deficient
macrophages stimulated with LPS.
Taken together with our previous studies, the present data
indicate that GSTO1-1 is required for the activation of macrophages
by LPS and is a determinant of all the redox and metabolic changes
that occur. The activation of macrophages by LPS occurs through
several parallel pathways that include the activation of NF-κB, and
the development of a glycolytic phenotype discussed above
(Fig. 6A). Both these pathways promote the production of ROS
and the expression of pro-inflammatory cytokines, such as IL-1β.
The finding that GSTO1-1 deficiency blocks both activation
pathways places the site of GSTO1-1 action upstream and
possibly in the TLR4–myddosome complex (Fig. 6A).
These findings identify GSTO1-1 as a new anti-inflammatory
target. Indeed, the treatment of LPS-stimulated J774.1A cells with
the GSTO1-1 inhibitor ML175 blocked all the metabolic effects
associated with macrophage activation including the generation
of ROS, the induction of COX2 and iNOS, the accumulation
of HIF1α, and the increase in lactate production through
glycolysis. The observation that the effects of ML175 are dose
dependent provides additional evidence that inflammation might be
pharmacologically targeted through the development of novel
GSTO1-1 inhibitors.
Given that a pharmacological inhibitor of GSTO1-1 was found to
be effective in blocking LPS stimulated activation it seems likely that
the regulatory effect of GSTO1-1 is mediated by its catalytic activity.
Several studies (Anathy et al., 2012; Cooper et al., 2011; Dalle-Donne
et al., 2009; Lim et al., 2010) have suggested that protein
glutathionylation can provide a reversible switch that can regulate
protein function and potentially regulate pathways in a manor
analogous to protein phosphorylation.We have previously shown that
GSTO1-1 can catalyse glutathionylation cycle reactions (Menon and
Board, 2013) and in this studywe found that total glutathionylation of
proteins was significantly elevated in GSTO1-1-knockdown cells
compared with wild-type and non-silencing control cells (Fig. 6B).
Consequently, we speculate that GSTO1-1 regulates the TLR4
pathway by the reversible glutathionylation of a key protein.
Overall these findings support our hypothesis that GSTO1-1 is an
indispensable upstream modulator of TLR4-mediated responses
and is necessary for the maintenance of the metabolic and redox
re-profiling of LPS-activated macrophages.
MATERIALS AND METHODS
Materials
Unless otherwise indicated, all chemicals were purchased from Sigma-
Aldrich (St. Louis, MO). LPS (Escherichia coli O111:B4) was purchased
from Invitrogen. The primers used in this study were purchased from
Integrated DNATechnology (supplementary material Table S1). Antibodies
were purchased from Cell Signaling Technology (Danvers, MA).
The GSTO1-1 inhibitor ML175 {N-[3-(N-(2-chloroacetyl)-4-nitroanilino)
propyl]-2,2,2-trifluoroacetamide} is a hindered α-chloroacetamide
(Tsuboi et al., 2010) and was purchased from Vitas-M Laboratory (The
Netherlands).
Cell culture
Cells lines were purchased from ATCC and were maintained at 37°C,
under 5% CO2 and in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum. J774.1A murine macrophagic
Fig. 4. LPS-dependent
reprogramming of the TCA cycle in
M1 macrophages is altered by
GSTO1-1 knockdown. (A,B) The
accumulation of succinate and fumarate




Data was normalized to levels of Leu, Ile
or Met. (C) Citrate levels also remained
unchanged in LPS-treated
GSTO1-knockdown macrophages.
HIF1α is stabilized by LPS stimulation of
macrophages. (D) The accumulation of
F6P in LPS-stimulated J744 non-
silencing control macrophages is
attenuated in GSTO1-1-deficient cells.
(E) The induction of HIF1α stimulated by
LPS in J744 non-silencing
macrophages is significantly attenuated
in GSTO1-1-deficient cells. (F) Inhibition
of GSTO1-1 catalytic activity with
ML175 mimicked the effects of silencing
GSTO1 in macrophages in a dose-
dependent manner. All data are shown
as the mean±s.e.m. (n=3).
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cells transfected with a lentiviral plasmid encoding a GSTO1 short
hairpin RNA (shRNA) and non-silencing control scrambled shRNA were
generated as previously described (Menon et al., 2014). The efficient
knockdown of GSTO1-1 by lentiviral shRNA expression is confirmed
in Fig. 2B. In all cell culture experiments, LPS was used at a concentration of
10 ng/ml.
Immunoblotting
SDS-PAGE and non-reducing SDS-PAGE were performed as described
previously (Laemmli, 1970). Separated proteins were transferred onto
nitrocellulose membranes (Towbin et al., 1979) and immunodetected using
primary antibodies at a 1:1000 dilution and probed with a goat
anti-rabbit IgG horseradish-peroxidase-conjugated secondary antibody
(Dako). Chemiluminescence was detected by the ECL Rapid Step
chemiluminescence detection system (Calbiochem, Merck, Germany).
Quantification of the cellular glutathione pool
The assay was carried out as described previously (Rahman et al., 2006). For
oxidized glutathione, 100 µl of sample or GSSG standards were treated with
10% 2-vinylpyridine (10 µl) for 1 h followed by pH neutralization with 6%
triethanolamine (6 µl). For reduced glutathione, 100 μl of sample or GSH
standards was assayed directly. Samples were incubated with pre-mixed
5,5′-dithiobis-2-nitrobenzoic acid (DTNB) (0.67 mg/ml) and glutathione
reductase (250 U/ml) for 30-s–1-min as per protocol and mixed with
NADPH (0.67 mg/ml) and the reaction rate was immediately recorded at
412 nm using a microplate reader.
Real-time RT-PCR
Total RNA was extracted from cells in trizol (Invitrogen) and a Qiagen
RNA extraction kit. The extracted RNA was treated with DNase to
remove genomic DNA contamination (Ambion DNase kit), and cDNA
Fig. 5. GSTO1-1 is required for bacterial
phagocytosis. (A) Phagocytosis of dead bacteria in
GSTO1-1-deficient macrophages was substantially
attenuated. (B) Cell viability remained unchanged
between the non-silencing control and GSTO1-
knockdown cells. (C,D) LPS-stimulated TLR4-
dependent phagocytosis was specifically blocked in
GSTO1-1-deficient cells. The nucleus is stained with
DAPI (blue), the plasma membrane is indicated by actin
staining (green) and LPS-coated latex beads are shown
in red. (E) The number of beads taken up was evaluated
in 200 cells per treatment group from three replicated
experiments. All data are shown as the mean±s.e.m.
(n=3).
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was synthesized by the use of an Invitrogen first-strand cDNA synthesis
kit. Real-time PCR was carried out on an ABI 7900HT thermocycler
and relative transcript levels were calculated by the ΔΔCt method using
GAPDH as an internal control to which all transcripts were normalized.
Primer sequences are provided in supplementary material Table S1.
Measuring mitochondrial ROS
Cells were seeded in six-well dishes at a cell density of 5×105 cells per
well and were treated with LPS as indicated. Cells were washed with PBS
and then incubated with MitoSOX and Mitotracker (Life Technologies) for
30 min at 37°C. Cells were washed twice and resuspended in PBS and
analysed by fluorescence-activated cell sorting (FACS) analysis. All
measurements were normalized against baseline readings from unstained
controls and then to untreated controls from each cell type. Data from three
independent experiments was analysed using Flowjo FACS analysis
software.
Determining mitochondrial membrane potential
Treated or untreated cells (105), were resuspended in 1 ml warm PBS. As a
positive control, cells were treated with 50 µM Carbonyl cyanide
m-chlorophenyl hydrazone (CCCP) for 5 min. Cells were incubated with
JC-1 dye (Mitoprobe, Life Technologies) at 37°C, under 5% CO2 for 30 min
according to the manufacturer’s instructions. Cells were then washed with
PBS and resuspended in 100 μl of PBS and analysed by FACS with an
emission wavelength of 488 nm. Data from three independent experiments
was analysed using Flowjo FACS analysis software.
Measurement of extracellular lactate levels
Cells were seeded in six-well dishes at a density of 5×105 cells per well
and treated with LPS as indicated. Briefly, medium was collected at
different time points and mixed with 3% perchloric acid. 0.05% Methyl
Orange was then added to the samples (final concentration of
0.00083%) and mixed well. The pH of the samples was raised with
1M K2CO3 until the solution turned bright yellow. The volume was
adjusted to 400 µl and 1/10th of the total volume (40 µl) was then
incubated with NAD (1 mM) in a glycine hydrazine buffer (1 M glycine,
0.4 M hydrazine sulphate, 5 mM EDTA and 0.5 M NaOH) and initial
absorbance was measured at 340 nm at 37°C. The samples were then
mixed with 19.8 U lactate dehydrogenase and absorbance was recorded
every 10 min at 340 nm at 37°C. The initial absorbance values were
subtracted from the final readings and lactate concentrations were
calculated based on the standard curve obtained from standards made
from sodium lactate.
Measurement of NADPH and NADP+ levels
Cellular NADPH and NADP levels were estimated by an enzymatic assay
(Abnova). Briefly, 105 cells were lysed in either NADP or NADPH
extraction buffer and heated at 60°C for 5 min. Samples were neutralized
with the opposite buffer and centrifuged at 14,000 g for 10 min to remove all
debris. The supernatant was incubated with the reaction buffer (containing
MTT, glucose and glucose dehydrogenase) and absorbance was
immediately read at 565 nm. The reaction was allowed to progress
at room temperature and the final absorbance was measured after 30 min.
The initial absorbance values were subtracted from the final readings, and
NADPH:NADP ratios were calculated based on NADP standards.
Extracellular flux measurements
For real-time analysis of the bioenergetics profile of activated macrophages
(OCR and ECAR), cells were analysed with an XFe-96 Extracellular Flux
Analyser (Seahorse Bioscience) as described previously (Freemerman et al.,
2014; Haschemi et al., 2012). Cells were seeded at a density of 130,000 cells
per well in XFe 96 plates and treated with LPS as indicated. The cells were
washed and allowed to recover in XF medium supplemented with 5.5 mM
glucose and 1 mM pyruvate for 1 h at 37°C without CO2. The OCR and
ECAR were measured and results were normalized to readings from
untreated cells at the respective time points.
Fig. 6. A scheme proposed for the role of GSTO1-1 in the development of LPS- and TLR4-mediated inflammation. (A) GSTO1-1 deficiency or its inhibition
with ML175 blocks the activation of NF-κB, the generation of cytosolic and mitochondrial ROS, and the switch to a glycolytic phenotype characterized by the
accumulation of succinate and the stabilization of HIF1α. These effects block pro-inflammatory cytokine production that leads to inflammation. The available
evidence suggests that GSTO1-1 targets a protein in the myddsome shown in the red box. (B) GSTO1-1 deficiency leads to a significant (**P<0.01) increase in
total protein glutathionylation. Data are shown as the mean±s.e.m. (n=3).
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GC-MS analysis of metabolites in macrophages
For gas-chromatography–mass-spectrometry (GC-MS) analysis, cells
were seeded at a density of 5×105 cells per well in six-well dishes and
treated with LPS as indicated. Post treatment, cells were lysed in a 1:1
methanol and water solution and derivitized in methoxyamine, HCl in
anhydrous pyridine and N-methyl-N-(trimethylsilyl)-trifluoroacetamide.
The derivatized samples were analysed by GC-MS with a full scan range
of 50–600m/z transition (Agilent 7890A, Agilent 5975CMS inert XL EI/CI
MSD with triple axis detector, Inc. Santa Clara, CA). Metabolites were
screened using AnalyzerPro and identified against the NSIT library. The
peak area of Kreb’s intermediates succinate and fumarate were normalized
to essential amino acids in each sample. All readings were measured in
triplicate.
LC-MS/MS analysis of metabolites in macrophages
For liquid-chromatography–tandem-mass-spectrometry (LC-MS/MS) analysis,
cells were seeded at a density of 5×105 cells per well in six-well dishes and
treated with LPS as indicated. Post treatment, cells were washed with PBS
and lysed in a 1:1 methanol and water solution and pre-treated as described
above for the GC-MS sample preparation. The supernatant was dried using a
vacuum concentrator (Savant Speedvac) and resuspended along with the
standards in double distilled degassed water. Samples were vortexed and
filtered through a 0.45 µm GHP membrane in a Nanosep MF Centrifuge
tube (Pall Co., Port Washington, WI) before LC-MS/MS analysis. Sugar
phosphates and other metabolic intermediates were analysed using an
optimized Agilent 6530 Accurate-Mass Q-TOF LC/MS (Agilent
Technologies, Inc. Santa Clara, CA) at the ANU Mass Spectrometry
Facility. Samples were subjected to optimized electrospray ionization (ESI)
in the Jetstream interface in negative polarity under the following
conditions: gas temperature 250°C, drying gas 9 l min−1, nebulizer 25
psig (172.4 kPa), sheath gas temperature 250°C and flow rate of 11 l min−1,
capillary voltage 2500V, fragmentor 145V, and nozzle voltage 500V.Mobile
phase A consisted of water with 0.1% formic acid and mobile phase B
consisted of 90%methanol, 10%water and 0.1% formic acid. Samples were
injected onto an Agilent Phonomenex Luna 3U HILIC 200A (50×2 mm,
3 micron) column and analytes were eluted in mobile phase B. The
quadrupole-time-of-flight (QTOF) was operated in targeted MS/MS mode
using collision-induced dissociation [CID; N2 collision gas supplied at
18 psi (124.1 kPa), m/z 1.3 isolation window] where the MS extended
dynamic range was set from m/z 100–1000 at three spectra s−1, and MS/MS
m/z 50–1000 at three spectra s−1. Data was extracted and analysed using
Agilent Technologies Masshunter software.
Phagocytosis assay
Phagocytosis of fluorescently labelled dead E. coli (strain K-12) was
measured as per manufacturer’s instructions (Vybrant phagocytosis kit,
Life Technologies). J774.1A cells were seeded in 96-well plates at a
density of 105 cells per well and allowed to adhere for 2 h at 37°C, 5%
CO2. Medium was removed and the cells were incubated in the
fluorescent bioparticle suspension for 2 h. The supernatant was then
removed and Trypan Blue was added to each well at a final concentration
of 250 µg/ml and allowed to sit for 1 min. The wells were washed and
fluorescence was measured at an excitation and emission wavelength of
480 and 520 nm, respectively, using a plate reader (Fluostar Optima). Net
phagocytosis of GSTO1-1 knockdown cells was determined by
subtracting the average fluorescence of media-only negative control
wells and normalizing to the average fluorescence of the non-silencing
control J774.1A macrophages. The cells were then lysed in 1% SDS and
cell viability was determined by measuring absorbance of Trypan Blue at
590 nm (Uliasz and Hewett, 2000).
Latex bead phagocytosis assay
Yellow–orange 3-μm Fluoresbrite carboxy latex microparticles
(Polysciences) were incubated with 30 µg/ml LPS overnight at 4°C in
PBS. Beads were then washed thoroughly in PBS to remove unbound LPS.
Cells cultured overnight on coverslips in 12-well plates were incubated on
ice for 10 min. LPS-coated and uncoated (control) latex beads were added to
the cells and allowed to settle on the cells for 10 min prior to incubation in
warm culture medium at 37°C for indicated time periods. Cells were fixed
with 3.7% paraformaldehyde for 15 min at room temperature, permeabilized
with 0.1% Triton X-100 and 0.2% BSA and stained with phalloidin–FITC
(Sigma) as per the manufacturer’s instructions. The intracellular uptake
of the beads was visualized by confocal microscopy (Leica SP5). Serial
z-sections were recorded to confirm intracellular localization of the beads.
The number of beads taken up was assessed in 200 cells per treatment group
across 30 cells per coverslip.
Statistical analysis
Data were expressed as the mean±s.e.m. and analysed using Prism 4
(Graphpad software Inc.). Statistical significance was calculated by standard
Student’s t-tests. All experiments were performed in triplicate unless
otherwise stated. Statistical significance was shown as *P≤0.05, **P<0.01
and ***P<0.001.
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Thelen, K. M., Kreis, M., Hentschel, F., Schulz, A. et al. (2004). Polymorphisms
in glutathione S-transferase omega-1 and AD, vascular dementia, and stroke.
Neurology 63, 2255-2260.
Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of the
head of bacteriophage T4. Nature 227, 680-685.
Li, Y. J., Oliveira, S. A., Xu, P., Martin, E. R., Stenger, J. E., Scherzer, C. R.,
Hauser, M. A., Scott, W. K., Small, G.W., Nance, M. A. et al. (2003). Glutathione
S-transferase omega-1 modifies age-at-onset of Alzheimer disease and
Parkinson disease. Hum. Mol. Genet. 12, 3259-3267.
Lim, S. Y., Raftery, M. J., Goyette, J. and Geczy, C. L. (2010). S-glutathionylation
regulates inflammatory activities of S100A9. J. Biol. Chem. 285, 14377-14388.
Maitra, U., Singh, N., Gan, L., Ringwood, L. and Li, L. (2009). IRAK-1 contributes
to lipopolysaccharide-induced reactive oxygen species generation in
macrophages by inducing NOX-1 transcription and Rac1 activation and
suppressing the expression of antioxidative enzymes. J. Biol. Chem. 284,
35403-35411.
Matsuzawa, A., Saegusa, K., Noguchi, T., Sadamitsu, C., Nishitoh, H., Nagai, S.,
Koyasu, S., Matsumoto, K., Takeda, K. and Ichijo, H. (2005). ROS-dependent
activation of the TRAF6-ASK1-p38 pathway is selectively required for TLR4-
mediated innate immunity. Nat. Immunol. 6, 587-592.
Meissner, F., Molawi, K. and Zychlinsky, A. (2008). Superoxide dismutase 1
regulates caspase-1 and endotoxic shock. Nat. Immunol. 9, 866-872.
Menon, D. and Board, P. G. (2013). A role for glutathione transferase Omega 1
(GSTO1-1) in the glutathionylation cycle. J. Biol. Chem. 288, 25769-25779.
Menon, D., Coll, R., O’Neill, L. A. J. and Board, P. G. (2014). Glutathione
transferase omega 1 is required for the lipopolysaccharide-stimulated induction of
NADPH oxidase 1 and the production of reactive oxygen species inmacrophages.
Free Radic. Biol. Med. 73, 318-327.
Mo, C., Wang, L., Zhang, J., Numazawa, S., Tang, H., Tang, X., Han, X., Li, J.,
Yang, M., Wang, Z. et al. (2014). The crosstalk between Nrf2 and AMPK
signal pathways is important for the anti-inflammatory effect of berberine in
LPS-stimulated macrophages and endotoxin-shocked mice. Antioxid. Redox
Signal. 20, 574-588.
Piacentini, S., Polimanti, R., Squitti, R., Mariani, S., Migliore, S., Vernieri, F.,
Rossini, P. M., Manfellotto, D. and Fuciarelli, M. (2012). GSTO1*E155del
polymorphism associated with increased risk for late-onset Alzheimer’s disease:
association hypothesis for an uncommon genetic variant. Neurosci. Lett. 506,
203-207.
Poltorak, A., He, X., Smirnova, I., Liu, M.-Y., Van Huffel, C., Du, X., Birdwell, D.,
Alejos, E., Silva, M., Galanos, C. et al. (1998). Defective LPS signaling in C3H/
HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282, 2085-2088.
Rahman, I., Kode, A. and Biswas, S. K. (2006). Assay for quantitative
determination of glutathione and glutathione disulfide levels using enzymatic
recycling method. Nat. Protoc. 1, 3159-3165.
Raso, G. M., Meli, R., Di Carlo, G., Pacilio, M. and Di Carlo, R. (2001). Inhibition of
inducible nitric oxide synthase and cyclooxygenase-2 expression by flavonoids in
macrophage J774A.1. Life Sci. 68, 921-931.
Stoll, L. L., Denning, G. M. and Weintraub, N. L. (2006). Endotoxin, TLR4
signaling and vascular inflammation: potential therapeutic targets in
cardiovascular disease. Curr. Pharm. Des. 12, 4229-4245.
Tannahill, G. M., Curtis, A. M., Adamik, J., Palsson-McDermott, E. M.,
McGettrick, A. F., Goel, G., Frezza, C., Bernard, N. J., Kelly, B., Foley, N. H.
et al. (2013). Succinate is an inflammatory signal that induces IL-1β through HIF-
1α. Nature 496, 238-242.
Thimmulappa, R. K., Scollick, C., Traore, K., Yates, M., Trush, M. A., Liby, K. T.,
Sporn, M. B., Yamamoto, M., Kensler, T. W. and Biswal, S. (2006). Nrf2-
dependent protection from LPS induced inflammatory response and mortality by
CDDO-Imidazolide. Biochem. Biophys. Res. Commun. 351, 883-889.
Towbin, H., Staehelin, T. and Gordon, J. (1979). Electrophoretic transfer of
proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some
applications. Proc. Natl. Acad. Sci. USA 76, 4350-4354.
Tsuboi, K., Bachovchin, D. A., Speers, A. E., Brown, S. J., Spicer, T.,
Fernandez-Vega, V., Ferguson, J., Cravatt, B. F., Hodder, P. and Rosen, H.
(2010). Optimization and characterization of an inhibitor for glutathione S-
tranferase omega 1 (GSTO1). In Probe Reports from the NIH Molecular Libraries
Program (ed. NCBI (US)). Bethesda, MD: NCBI.
Uliasz, T. F. and Hewett, S. J. (2000). A microtiter trypan blue absorbance assay for
the quantitative determination of excitotoxic neuronal injury in cell culture.
J. Neurosci. Methods 100, 157-163.
Wadleigh, D. J., Reddy, S. T., Kopp, E., Ghosh, S. and Herschman, H. R. (2000).
Transcriptional activation of the cyclooxygenase-2 gene in endotoxin-treated
RAW 264.7 macrophages. J. Biol. Chem. 275, 6259-6266.
West, A. P., Brodsky, I. E., Rahner, C., Woo, D. K., Erdjument-Bromage, H.,
Tempst, P., Walsh, M. C., Choi, Y., Shadel, G. S. and Ghosh, S. (2011). TLR
signalling augments macrophage bactericidal activity throughmitochondrial ROS.
Nature 472, 476-480.
Zhang, G. andGhosh, S. (2001). Toll-like receptor-mediated NF-kappaB activation:
a phylogenetically conserved paradigm in innate immunity. J. Clin. Invest. 107,
13-19.
Zhou, R., Tardivel, A., Thorens, B., Choi, I. and Tschopp, J. (2010). Thioredoxin-
interacting protein links oxidative stress to inflammasome activation. Nat.
Immunol. 11, 136-140.
1990
RESEARCH ARTICLE Journal of Cell Science (2015) 128, 1982-1990 doi:10.1242/jcs.167858
Jo
u
rn
al
o
f
Ce
ll
Sc
ie
n
ce
